Tailored vaccines – fantasy or reality? Irini Doytchinova Medical University of Sofia School of Pharmacy, Medical University of Sofia.

Slides:



Advertisements
Similar presentations
Major Histocompatibility Complex. Principles of Immune Response Highly specific recognition of foreign antigens Mechanisms for elimination of microbes.
Advertisements

Antigen Presentation K.J. Goodrum Department of Biomedical Sciences Ohio University 2005.
T-cell epitope prediction by molecular dynamics simulations Irini Doytchinova Medical University of Sofia School of Pharmacy Medical University of Sofia.
Hotspot Hunter: a computational system for large-scale screening and selection of candidate immunological hotspots in pathogen proteomes G.L. Zhang, A.M.
Vaxil BioTherapeutics Ltd.
HLA TYPING D Middleton MDSC175: Transplantation Science for Transplant Clinicians (Online) POSTGRADUATE SCHOOL OF MEDICINE A MEMBER OF THE RUSSELL GROUP.
CENTER FOR BIOLOGICAL SEQUENCE ANALYSISTECHNICAL UNIVERSITY OF DENMARK DTU T cell Epitope predictions using bioinformatics (Neural Networks and hidden.
Slide 1 of 38 T-cell EPITOPES PREDICTION OF HEMAGGLUTININ, NEURAMINIDASE AND MATRIX PROTEIN OF INFLUENZA A VIRUS USING SUPPORT VECTOR MACHINE AND HIDDEN.
Lecture outline Capture of antigens from sites of entry and display of antigens to T cells Function of MHC molecules as the peptide display molecules of.
Structural Immunoinformatics – two case studies M. Atanasova, I. Dimitrov, A. Patronov, I. Doytchinova Medical University of SofiaFaculty of Pharmacy Regional.
Lecture 3 clinical immunology Antigen Presenting Cells
Computer Aided Vaccine Design Dr G P S Raghava. Concept of Drug and Vaccine Concept of Drug Concept of Drug –Kill invaders of foreign pathogens –Inhibit.
Molecular dynamics refinement and rescoring in WISDOM virtual screenings Gianluca Degliesposti University of Modena and Reggio Emilia Molecular Modelling.
MHC Polymorphism Ole Lund. Objectives What is HLA polymorphism? What is it good for? How does it make life difficult for vaccine design? Definition of.
Development of methods for the analysis of ligand-protein interactions by Maris Lapinsh; Advisor Jarl Wikberg Division of Pharmacology, Uppsala University.
Computational Immunology An Introduction Rose Hoberman BioLM Seminar April 2003.
Bioinformatics pipeline for detection of immunogenic cancer mutations by high throughput mRNA sequencing Jorge Duitama 1, Ion Mandoiu 1, and Pramod Srivastava.
MHC Polymorphism. MHC Class I pathway Figure by Eric A.J. Reits.
Pattern recognition in the immune system. Specific peptide recognition Antibody epitopes T-cell receptors recognizing peptides presented on MHC-molecules.
Selection of T Cell Epitopes Using an Integrative Approach Mette Voldby Larsen cand. scient. in biology ph.d. student.
Protein Therapeutics Immunogenicity Stephen Lynn CHEM645 0.
Epitope Selection Rational Vaccine design. Why? Therapeutic vaccines Therapeutic vaccines Treatment of viral infections (e.g., HIV, HCV), and resistant.
This document provides an outline of a presentation and is incomplete without the accompanying oral commentary and discussion. Conclusions and/ or potential.
Institute of Microbial Technology, Chandigarh, India
Prediction of CTL responses Mette Voldby Larsen cand. scient. in biology ph.d. student.
Antigen Presentation Fundamentals I for Dentistry & Optometry Textbook: Medical Microbiology, 6 th Edition, Murray Chapter 11 Jim Collawn, MCLM 350
An in vitro selection technique using a peptide or protein genetically fused to the coat protein of a bacteriophage.
BIOT 307 Kuby, Ch. 3, Antigens March, General Introduction Specificity due to recognition of antigenic determinants or epitopes Epitopes = immunologically.
Lecture outline Capture of antigens from sites of entry and display of antigens to T cells Function of MHC molecules as the peptide display molecules of.
Institute of Immunology, ZJU
Methods MHC class-I T cell epitope prediction for Nef Consensus and ancestral sequences of the Nef protein for the different HIV-1 subtypes were obtained.
PLASMA CELL ANTIGEN CYTOKINES B -CELL T – CELLS PROMOTE B – CELL DIFFERENTIATION ISOTYPE SWITCH AND AFFINITY MATURATION OCCURS IN COLLABORATION WITH T.
Selection of T Cell Epitopes Using an Integrative Approach Mette Voldby Larsen cand. scient. in Biology PhD in Immunological Bioinformatics.
Institute of Microbial Technology, Chandigarh, India
The Major Histocompatibility Complex (MHC) In all vertebrates there is a genetic region that has a major influence on graft survival This region is referred.
PART II. Prediction of functional regions within disordered proteins Zsuzsanna Dosztányi MTA-ELTE Momentum Bioinformatics Group Department of Biochemistry.
School of Pharmacy Medical University of Sofia
1 Computer-aided Subunit Vaccine Design G.P.S. Raghava, Institute of Microbial Technology, Chandigarh  Understanding immune system  Breaking complex.
MHC and AG Presentation1 MHC and Antigen Presentation Chapters 6 & 7 Self-Test Questions: Chap 6 A: 1 – 5, 8 Note: for A-5 know MHC I - III B – D: all.
Computational Vaccinology Darren R Flower
Biology of the B Lymphocyte Review: B cells can develop a vast repertoire of antigenic specificities Diversity – the ability to respond to many different.
Telling self from non-self: Learning the language of the Immune System Rose Hoberman and Roni Rosenfeld BioLM Workshop May 2003.
Structural Bioinformatics Section Vaccine Research Center/NIAID/NIH
Structural Modelling and Bioinformatics in Drug Discovery and Infectious Disease Shoba Ranganathan Professor and Chair – Bioinformatics Dept. of Chemistry.
1 Web Site: Dr. G P S Raghava, Head Bioinformatics Centre Institute of Microbial Technology, Chandigarh, India Prediction.
BioinformaticsDrug InformaticsVaccine Informatics Chemoinformatics
Statistical physics of T cell receptor selection and function Thesis committee meeting, 04/15/2009 Andrej Košmrlj Physics Department Massachusetts Institute.
Electrostatic Potential on HLA-DPB1*1701 and HLA-DPB1*0401: Implications for Putative Mechanism of Chronic Beryllium Disease Health Effects Laboratory.
Vaccines: A Molecular View
MAJOR HISTOCOMPATIBILITY COMPLEX
T – CELLS PROMOTE B – CELL DIFFERENTIATION
Bioinformatics in Vaccine Design
Discovery of Therapeutics to Improve Quality of Life Ram Samudrala University of Washington.
Prediction of T cell epitopes using artificial neural networks Morten Nielsen, CBS, BioCentrum, DTU.
Lecture 13 Immunology and disease: parasite antigenic diversity.
Janeway’s Immunobiology
Molecular Modeling in Drug Discovery: an Overview
Structure-based inhibitor design and validation: Application to Plasmodium falciparum glutathione S-transferase Marli Botha MSc. Bioinformatics.
IMMUNOGRID Nikolai Petrovsky and Vladimir Brusic
Immunoinformatics Approach for Non-Small Cell Lung Cancer
MAJOR HISTOCOMPATIBILITY COMPLEX
Computer-aided Vaccine and Drug Discovery G. P. S
Intracellular Pathogens Extracellular Pathogens
The Major Histocompatibility Complex (MHC)
Immunology and disease: parasite antigenic diversity
Ligand Docking to MHC Class I Molecules
Experimental methods in classic epitope discovery
An Integrated Approach to Protein-Protein Docking
Towards epitope matching in kidney allocation
Telling self from non-self: Learning the language of the Immune System
Presentation transcript:

Tailored vaccines – fantasy or reality? Irini Doytchinova Medical University of Sofia School of Pharmacy, Medical University of Sofia

Vaccines and Epitopes live attenuated or killed pathogens subunit vaccines epitope-based vaccines Epitope is a continuous or non-continuous sequence of a protein that is recognized by and interacts with other protein. linear epitope conformational epitope Т-lymphocyte В-limphocyte

Antigen processing pathways Intracellular pathway Extracellular pathway

T-cell epitope prediction in vitro and in vivo tests clinical tests Epitope-based vaccine development in silico prediction 100 aa 92 overlapping nonamer peptides 10 nonamer peptides

T-cell epitope prediction = MHC binding prediction The number of T-cell receptors (TCRs) within the human T-cell repertoire has been estimated between 10 7 and IMGT/HLA Database (Sept. 2011) HLA class I 5,301 HLA class II1,509 All6,810 MHC binders T-cell epitopes All T-cell epitopes are MHC binders, but not all MHC binders are T-cell epitopes. 90% of the T-cell epitopes have MHC affinity stronger than 500 nM. Aim: To identify the best MHC binders (the top 2% of all peptides generated from one protein).

Peptide binding site on MHC MHC class IMHC class II

Allele frequency in Bulgarian population The Allele Frequency Net Database ( September 2011 n = 55

Peptide vaccines are tailored drugs Cocktail of many epitopes each binding to one MHC protein A few promiscuous epitopes each binding to several MHC proteins

Immunoinformatics approaches Sequence-based methodsStructure-based methods peptide pIC50exp ILDPFPVTV ALDPFPPTV VLDPFPITV LLDPFPPPV ILDPIPPTV LLDDFPVTV ILDPLPPTV YLFPGPVTA Affinity = f (Chemical Structure) Motif-based, QMs, ANN, SVM Affinity = f (Interaction energy) Molecular docking, Molecular dynamics

Our immunoinformatics tools

Server for in silico prediction of peptides binding to MHC proteins Additive sequence-based method Guan et al. Nucleic Acid Res., 31, , 2003; Guan et al. Appl. Bioinformatics, 2, 63-66, 2003; Guan et al. Appl. Bioinformatics, 5, 55-61, 2006 HLA class I: 11 alleles A*0101 А*0201, А*0202, А*0203, А*0206 А*0301, А*1101, А*3101 А*6801, А*6802 B*3501 HLA class II: 3 alleles DRB1*0101, DRB1*0401, DRB1*0701 mouse MHC class I: 3 alleles H2-Db, H2-Kb, H2-Kk mouse MHC class II: 6 alleles I-Ab, I-Ad, I-Ak, I-As I-Ed, I-Ek MHCPred

HIV epitope project Walshe et al. PLoS ONE, 4, e8095, 2009 training set of 43 peptides 25 binders + 18 non-binders model for binding to HLA-Cw* predicted binders 11 true binders 1 new epitope recognized by T cells experimentally tested virtual screening on HIV proteome additive PLS method experimentally tested Collaborators: Leiden University Medical School UCL Medical School Funding: The Jenner Institute, Oxford University Human Immunodeficiency Virus (HIV)

EpiJen Server for in silico prediction of T-cell epitopes binding to MHC class I proteins Multi-step algorithm based on the additive method QM for proteasome cleavage QM for ТАР affinity QMs for MHC affinity T-cell recognition non-cleaved non-transported non-bound cleaved transported bound non-recognized top 5% Doytchinova et al. J. Immunol., 173, , 2004; Doytchinova & Flower. Mol. Immun., 43, , 2006; Doytchinova et al. BMC Bioinformatics, 7, 131, 2006

VaxiJen Doytchinova and Flower, Vaccine, 25, 856, 2007; Doytchinova and Flower, BMC Bioinformatics, 8, 4, 2007; Doytchinova and Flower, The Open Vaccine J., 1, 22, 2008 training set of proteins immunogens + non-immunogens uniform set of proteins model for immunogenicity prediction assessment of sensitivity, specificity and accuracy CV and external validation discriminant analysis by PLS z-descriptors + ACC transformation Training setAccuracy % Bacterial70 Viral70 Tumor86 Parasite79 Fungal97 Server for in silico prediction of immunogens and subunit vaccines

EpiTOP Server for proteochemometrics-based prediction of peptides binding to MHC class II proteins Affinity = L + P + LP Dimitrov et al., Bioinformatics 26, 2066, training set of 2666 peptides binding to 12 HLA-DRB1 proteins models for binding prediction EpiTOP Proteochemometric QSAR CV and external validation Proteochemometrics is a QSAR method specially designed to deal with ligands binding to a set of similar proteins. Prof. Jarl Wikberg – Uppsala University, Sweden

MHC class II binding prediction by structure-based methods Combinatorial library binding score PKYVKQNTLKLAT PKXVKQNTLKLAT PKYXKQNTLKLAT … PKYVXQNTLKLAT … PKYVKXNTLKLAT … PKYVKQXTLKLAT … A … … … … … … … … … C … … … … … … … … … D … … … … … … … … … E … … … … … … … … … … … … … … External validation Quantitative Matrix Peptide – HLA-DP2 protein complex (DPA1*0103 red, DPB1*0101 blue) pdb code: 3lqz, April 2010

External validation Test set of 457 known binders to HLA-DP2 protein originating from 24 foreign proteins Immune Epitope Database: Peptidescore Score = X p1 + X p2 + X p3 + X p4 + X p5 + X p6 + X p7 + X p8 + X p9 MGHRTYYKL0.567 GHRTYYKLP1.245 HRTYYKLPR2.935 RTYYKLPRT TYYKLPRTT3.719 YYKLPRTTN1.543 YKLPRTTNV0.451 KLPRTTNVD2.039 TYYKLPRTT3.719 HRTYYKLPR2.935 KLPRTTNVD2.039 YYKLPRTTN1.543 GHRTYYKLP1.245 MGHRTYYKL0.567 YKLPRTTNV0.451 RTYYKLPRT Peptidescore ranking top 5%

Structural Immunoinformatics Method Sensitivity at the top 5% Time Molecular docking by GOLD on PC by AutoDock on BlueGene-P 42% 38% a batch of 20 complexes 1 week min Molecular dynamics by GROMACS on BlueGene-P33% one complex for 1 ns 11 hours Patronov et al. BMC Str. Biol., 11, 32, 2011; Doytchinova et al. Protein Science, in press.

EpiDOCK Server for structure-based prediction of peptides binding to MHC proteins HLA-DR: 12 alleles DRB1*0101, DRB1*0301, DRB1*0401, DRB1*0404, DRB1*0405, DRB1*0701, DRB1*0802, DRB1*0901, DRB1*1101, DRB1*1201, DRB1*1302, DRB1*1501 HLA-DQ: 6 alleles DQ2: DQA1*0501/DQB1*0201 DQ3:DQA1*0501/DQB1*0301 DQ3: DQA1*0301/DQB1*0302 DQ4: DQA1*0401/DQB1*0402 DQ5: DQA1*0101/DQB1*0501 DQ6: DQA1*0102/DQB1*0602 HLA-DP: 5 alleles DP1: HLA-DPA1*0201/HLA-DPB1*0101 DP2: HLA-DPA1*0103/HLA-DPB1*0201 DP4: HLA-DPA1*0103/HLA-DPB1*0401 DP4: HLA-DPA1*0103/HLA-DPB1*0402 DP5: HLA-DPA1*0201/HLA-DPB1*0501 SLA-1: 4 alleles SLA-1*0101, SLA-1*0401, SLA-1*0501, SLA-1*1101 Atanasova et al. Mol. Informatics, 30, 368, 2011

Activity on our servers Top 5 countries visiting: 1.India 2.USA 3.EU countries 4.Japan 5.Iran Top 5 servers used: 1.VaxiJen 2.MHCPred 3.AntiJen 4.EpiJen 5.EpiTOP

Current projects Anti-SIV vaccine project Collaborators: CReSA (Spanish private foundation for research in animal health) INIA (Spanish National Institute of Agriculture and Food Research) Funding: Spanish Ministry of Science Anti-tick vaccine project Collaborator: University of Pretoria, SA Funding: University of Pretoria, SA Boophilus microplus Swine Influenza Virus (SIV)

Acknowledgements All models are wrong but some are useful. George E. P. Box, 1987 Professor of Statistics, University of Wisconsin Darren R. Flower Aston University, Birmingham, UK Ivan Dimitrov Mariyana Atanasova Panaiot Garnev School of Pharmacy Medical University of Sofia Funding: National Research Fund, Ministry of Education and Science, Bulgaria, SuperCA (Grant 2-115/2008) and SuperCA++ (Grant 02-1/2009) Peicho Petkov School of Physics, University of Sofia Atanas Patronov Hannover Biomedical Research School, Germany